Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Research Bridge Partners
Deal Size : $2.0 million
Deal Type : Financing
Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies
Details : Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.
Brand Name : ASX-100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Research Bridge Partners
Deal Size : $2.0 million
Deal Type : Financing
Lead Product(s) : ASX-100
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Orange Grove Bio
Deal Size : Undisclosed
Deal Type : Funding
Details : ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials...
Brand Name : ASX-100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 25, 2020
Lead Product(s) : ASX-100
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Orange Grove Bio
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
